RIVASTIGMINE DEXCEL 1.5 MG Israel - English - Ministry of Health

rivastigmine dexcel 1.5 mg

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 1.5 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

RIVASTIGMINE DEXCEL 3 MG Israel - English - Ministry of Health

rivastigmine dexcel 3 mg

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 3 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

RIVASTIGMINE DEXCEL 4.5 MG Israel - English - Ministry of Health

rivastigmine dexcel 4.5 mg

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 4.5 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

RIVASTIGMINE DEXCEL 6 MG Israel - English - Ministry of Health

rivastigmine dexcel 6 mg

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 6 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Axura European Union - English - EMA (European Medicines Agency)

axura

merz pharmaceuticals gmbh - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer's disease.

Ebixa European Union - English - EMA (European Medicines Agency)

ebixa

h. lundbeck a/s - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer's disease.

Memantine Merz European Union - English - EMA (European Medicines Agency)

memantine merz

merz pharmaceuticals gmbh   - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer’s disease.

Memantine ratiopharm European Union - English - EMA (European Medicines Agency)

memantine ratiopharm

ratiopharm gmbh - memantine hydrochloride - alzheimer disease - psychoanaleptics, - treatment of patients with moderate to severe alzheimer’s disease

Exelon New Zealand - English - Medsafe (Medicines Safety Authority)

exelon

novartis new zealand ltd - rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine;   - capsule - 1.5 mg - active: rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

Exelon New Zealand - English - Medsafe (Medicines Safety Authority)

exelon

novartis new zealand ltd - rivastigmine tartrate 1.6mg equivalent to 1 mg rivastigmine - capsule - 1 mg - active: rivastigmine tartrate 1.6mg equivalent to 1 mg rivastigmine excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red iron oxide yellow   magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv titanium dioxide   - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.